Study #2019-0601
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy
MD Anderson Study Status
Enrolling
Treatment Agent
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Description
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostatic Neoplasms
Study phase:
Phase III
Physician name:
Christopher Logothetis
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-833-731-1107
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.